Heptares to Acquire G7 Therapeutics to Extend Leadership in GPCR-Focused Drug Discovery and Development

LONDON and ZURICH, November 30, 2016 /PRNewswire/ —
Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces it has signed a share purchase agreement that will allow the acquisition of 100% in G7 Therapeutics, a…
Source: PRNewsWire-USA

Heptares to Acquire G7 Therapeutics to Extend Leadership in GPCR-Focused Drug Discovery and Development